Physician profile
Cassandra E Curtis
NPI 1093808917
$180,891.48
in general payments reported to CMS, 2019-2025
54 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $50K · 2021: $61K · 2022: $50K · 2023: $1,931 · 2024: $1,349 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,705 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,704.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $875.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $55,798.83 | 2021-2025 | Qulipta, Ubrelvy |
| Allergan, INC. | $49,823.60 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $27,888.49 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $16,385.63 | 2022 | |
| Promius Pharma LLC | $14,747.17 | 2019 | |
| Genentech USA, INC. | $7,066.46 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,859.87 | 2019-2021 | |
| Emd Serono, INC. | $963.02 | 2019-2025 | Mavenclad, Mavenclad |
| Amgen INC. | $786.46 | 2019-2025 | Uplizna |
| Tg Therapeutics, INC. | $784.89 | 2023-2025 | |
| Genzyme Corporation | $678.94 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $659.08 | 2019-2021 | |
| Ucb, INC. | $340.98 | 2024-2025 | Zilbrysq, Rystiggo, Nayzilam |
| Harmony Biosciences LLC | $312.87 | 2023-2024 | Wakix |
| Horizon Therapeutics Plc | $251.36 | 2021-2023 | Uplizna |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $222.30 | 2024 | Vyepti |
| Pfizer INC. | $207.96 | 2019-2021 | |
| Novo Nordisk INC | $197.11 | 2019-2021 | |
| Livanova USA, INC. | $190.06 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $157.38 | 2020-2021 | |
| Abbott Laboratories | $136.55 | 2022-2024 | Freestyle Libre 3, Freestyle Libre |
| Medtronic, INC. | $135.65 | 2022-2025 | Intellis Adaptivestim |
| Exact Sciences Corporation | $132.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Avadel Cns Pharmaceuticals, LLC | $124.17 | 2023 | Lumryz |
| Kyowa Kirin, INC. | $117.68 | 2021 | |
| Acadia Pharmaceuticals INC | $109.65 | 2024 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $108.08 | 2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $74.08 | 2019-2025 | Capvaxive, Gardasil 9 |
| Lilly USA, LLC | $56.37 | 2019-2025 | Mounjaro, Zepbound |
| Dynavax Technologies Corporation | $54.24 | 2024 | Heplisav-B |
| Upsher-Smith Laboratories LLC | $54.16 | 2019-2020 | |
| Mdd US Operations, LLC | $39.80 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $37.92 | 2021 | |
| Dexcom, INC. | $35.01 | 2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $33.37 | 2020-2021 | |
| Inspire Medical Systems, INC. | $31.73 | 2023 | Inspire |
| Arbor Pharmaceuticals, INC. | $29.78 | 2021 | |
| Currax Pharmaceuticals LLC | $26.43 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.02 | 2021 | |
| Biogen, INC. | $19.13 | 2021 | |
| Glaxosmithkline, LLC. | $18.69 | 2025 | Shingrix, Arexvy |
| Eisai INC. | $18.56 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.49 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.38 | 2021 | |
| Mannkind Corporation | $16.29 | 2020 | |
| Avanir Pharmaceuticals, INC. | $15.22 | 2019 | |
| Coopersurgical, INC. | $14.28 | 2025 | Paragard T 380a |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.44 | 2019 | |
| Circassia INC. | $13.06 | 2019 | |
| Endo Pharmaceuticals INC. | $11.82 | 2020 | |
| Amarin Pharma, INC. | $11.76 | 2019 | |
| Mission Pharmacal Company | $11.52 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.45 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.